Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 mill...

Descripción completa

Detalles Bibliográficos
Autores principales: Ustianowski, Andrew, Arends, Joop E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4471058/
https://www.ncbi.nlm.nih.gov/pubmed/26032649
http://dx.doi.org/10.1007/s40121-015-0070-1
Descripción
Sumario:Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40121-015-0070-1) contains supplementary material, which is available to authorized users.

Ejemplares similares